New Trade for February 13th, 2023

Regardless of what’s happening elsewhere in the market, biopharma is a great place to look for stocks to pack into your portfolio because there’s always an illness that can be treated more effectively in the future than it is being treated today. 

Our trade alert features an established drug maker with an excellent approval history. Their treatments have been widely trusted for years, and currently, they have multiple promising projects in the pipeline. 

Behind the Markets:

Our #1 Small-Cap Stock for October

Ex-Wall Street CEO Dylan Jovine is one of the best Small-Cap investors on earth.

He’s delivered 435% profits on ChemoCentrix, 220% returns on Editas, 159% profits with Magnolia Gas and 194% with Scotts Miracle Gro.

[Get his #1 Small-Cap for October here >>>>>>]

Drugmaker, Viatris (VTRS) is profitable and looking for more growth. The company is in the process of trimming its less-profitable operations, including its biosimilars, women’s health division, and its over-the-counter drugs. In its place, it is adding an ophthalmology franchise through the $750 million acquisitions of Oyster Point Pharma and Famy Life Sciences. The deal is expected to close in the first quarter of 2023. Management expects the acquisition to generate at least $1 billion in sales by 2028.

[stock_market_widget type=”accordion” template=”extended” color=”#5679FF” assets=”VTRS” start_expanded=”true” display_currency_symbol=”true” api=”yf”]